The metabolic profile of the potent hypoglycemic agent, (2S)-pterosin A (1), in rat urine via intragastrical oral administration was investigated. In total, 19 metabolites (M1-M19) were identified. Among these, 16 metabolites were characterized by high-performance liquid chromatography solid-phase extraction-tube transfer-NMR, and seven metabolites were further isolated from the treated urine to enable further structural determination. Twelve of these are new compounds. The phase I metabolites of 1 were formed via various oxidations at positions C-3, C-10, C-12, C-13, or C-1 followed by decarboxylation of C-10 or C-14, and lactonization at C-12/C-14 or C-14/C-12. The phase II metabolites were glucuronide conjugates from the parent compound or phase I metabolites. The major metabolites were found to be (2S)-14-O-glucuronylpterosin A (M9), (2S)-2-hydroxymethylpterosin E (M14), and (؎)-pterosin B (M19). Quantitative HPLC analysis of metabolites, based on similar UV absorption and use of the regression equation of 1, indicated that ϳ71% 1 was excreted as metabolites in rat urine.
Introduction
Pteridium aquilinum (Dennstaedtiaceae), also called bracken, is widely used in preparations of traditional Chinese medicine that treat ailments of neonatal jaundice, hypertension, rheumatic arthritis, lower back pain, leucorrhoea, injury, and eczema (Wu, 1990) . However, some studies indicated the lethal properties of bracken ferns to cattle, resulting from urinary bladder cancer associated with chronic enzootic hematuria (Pamukcu et al., 1976; Castillo et al., 2003) or chromosome aberrations (Ojika et al., 1989; Lioi, 2004) . (2S)-Pterosin A (1), a sesquiterpene containing 1-indanone skeleton, is present in P. aquilinum and Pteridaceous plants . Some sesquiterpenes containing such skeleton have been reported to exhibit cytotoxicity to HeLa cells . A recent study revealed 1 to be a potent hypoglycemic agent (Hsu et al., 2010) . Our present study tried to establish the metabolic profile of compound 1 in rat, which would be useful in clarifying the potential toxicity and pharmacological effects of its metabolites.
Currently, hyphenated HPLC-NMR techniques provided a powerful tool for structure elucidation of noncrystalline organic compounds on an analytical scale. Prominent among these is the technique of HPLC-SPE-NMR, for which a SPE cartridge is used to trap multiple injections of a metabolite to enable sufficient accumulation for NMR measurement and thereby eliminating the eluent effect on 1 H NMR signals. Various studies successfully applied such a technique to identify the metabolites of drugs or bioactive compounds (Burton et al., 1997; Spraul et al., 2003; Godejohann et al., 2004; Sandvoss et al., 2005; Lai et al., 2010) and the constituents in complex natural products (Wang and Lee, 2005; Lam et al., 2007; Lee et al., 2007) . In the present study, HPLC-SPE-TT-NMR, which equipped a liquid handler between SPE and NMR to transfer compound from SPE to a 2-mm NMR tube for NMR measurement, and HPLC-HRESIMS were applied to characterize the metabolites of (2S)-pterosin A (1) in rat urine, collected in 24 h after intragastrical oral administration (Brant and Remon, 1991) . H. An analytical RP-HPLC column (Prodigy ODS3 100A, 250 ϫ 4.6 mm, 5 m; Phenomenex, Torrance, CA) was used in metabolites profiling, HPLC-SPE-TT-NMR, HPLC-MS, and quantitative analysis. A semipreparative RP-HPLC column (Prodigy ODS3 100A, 250 ϫ 10 mm, 5 m) was used for the isolation of metabolites. The 1 H, 13 C NMR, HSQC, and HMBC spectra, and NOEDS were measured either in a Quattro Nucleus probe of a 400 MHz Bruker Avance NMR spectrometer or in a Dual CryoProbe of a 600 MHz Bruker Avance III spectrometer (Bruker Daltonik, Billerica, MA) . MS spectra were measured in an Esquire 2000 ion trap mass spectrometer (Bruker Daltonik) and a Bruker Daltonics micrOTOF II time-of-flight mass spectrometer with electrospray ion sources.
Materials and Methods

Materials and Supplies. (2S)
Laboratory Animal. Male Wistar rats, 4 weeks old and weighing 210 to 240 g, were used as the experimental and the control groups (four in each group), and were obtained from the Laboratory Animal Center of National Taiwan University. The animal experiment was conducted according to a protocol approved by the Institutional Animal Care and Use Committee [National Taiwan University, Approval 95 (073)].
Animal Dosing and Sample Collection. Each rat was kept in an individual metabolic cage for 24 h before dosing. Normal food and water were available at all times. The suspension of (2S)-pterosin A (1, 100 mg/ml) in 10% aqueous acacia was prepared. The experimental rats were given 1, and the control rats were given vehicle via gavage, each 1 ml/kg. The totally administrated amounts of 1 were ϳ90 mg. The urine and feces were collected separately for 24 h.
Pretreatment and Fractionation of Urine Samples. The urine samples collected were 160 and 100 ml, respectively, for the treated and control groups, which were freeze-dried to yield the corresponding residues of 8.25 and 5.92 g. The urine residue from the treated group was fractionated by a Sephadex LH-20 column (MeOH-H 2 O 1:1) to give 10 fractions (U1-10), five of these contained metabolites (U3, 1.35 g; U5, 475.9 mg; U7, 81.9 mg; U8, 72.3 mg; U10, 107.1 mg), monitored by DAD and MS. To further concentrate the metabolites in fractions U3, -7, and -10, the suspension of each fraction in H 2 O (10 ml) was extracted by n-BuOH (10 ml ϫ 3) to give the corresponding n-BuOH soluble fraction (U3-B, 165.3 mg; U7-B, 26.8 mg; U10-B, 20.9 mg). The suspension of fraction U5 (465.4 mg), whose HPLC profile (Fig. 2b) showed two less polar metabolites (M18 and M19), in H 2 O (10 ml) was extracted by CHCl 3 (10 ml ϫ 3) to give a fraction rich in M18 and M19 (U5-C, 7.2 mg). Fraction U8 (71.7 mg) was further fractionated by a Sephadex LH-20 column (MeOH-H 2 O 7:3) to give three subfractions, of which subfraction 2 (U8-2, 2.0 mg) was metabolite-rich.
Pretreatment of Feces Sample. The wet feces samples collected were ϳ63.1 and 47.6 g for the treated and control groups, respectively. Each sample was divided into four parts. The mixture of each part and MeOH (20 ml) in a 50-ml centrifuge tube was vortexed for 5 min and then centrifuged at 2500 rpm for 10 min. The supernatant was collected, and the residue was treated in the same manner as for the wet feces sample for three times. The combined supernatants were evaporated under reduced pressure at 40°C to yield the MeOH extracts of 2.35 and 2.42 g for the treated and control groups, respectively. The MeOH extract (2.31 g) from the treated group was fractionated by a Sephadex LH-20 column (MeOH-H 2 O 7:3) to give six fractions (F1-6), of which fractions F2 (478.8 mg), F3 (281.7 mg), F4 (208.3 mg), and F5 (51.3 mg) contained metabolites monitored by DAD and MS.
Metabolites Profiling of Urine and Feces Samples by HPLC. Each of the urine and feces residues and the metabolite-containing fractions (U3-B, U5, U7, U8, U10, F2-5) was dissolved in MeOH, with the exception of the urine residues in water, and filtered through a membrane (0.45 m), and the filtrate was used for HPLC-DAD analysis. The HPLC conditions for metabolites profiling were as follows: an analytical RP-HPLC column as indicated above; delivery system, MeOH-0.1% FA aq 5:95 to 89:11 in 60 min by a linear gradient mode, and 89:11 for 10 min; flow rate 0.6 ml/min; samples and amount injected, 100 g/10 l (MeOH) for the feces residues (treated and control), 100 g/10 l (H 2 O) for the urine residues (treated and control), 50 g /10 l (MeOH) for fractions U3-B, U5, U7, U8, U10, and F2-5; detection at 260 nm.
Isolation of M1-M3, M9, M14, M18, and M19. Fraction U10-B was separated over a Sephadex LH-20 column (MeOH-H 2 O 7:3) to give M19 (1.6 mg). Fraction U7-B was fractionated by the same conditions for fraction U10-B to give a metabolite-containing fraction (U7-B-1, 9.2 mg), which was separated by the semi-preparative RP-HPLC column [2.3 mg/50 l (MeOH) ϫ 3], delivered by MeOH-0.1% FA aq 40:60, flow rate 2.8 ml/min, and monitored at 260 nm, to give M1 (0.2 mg, t R 11.2 min), M2 (0.4 mg, t R 17.0 min), and M3 (0.6 mg, t R 23.1 min). Fraction U5-C (1.25 mg/25 l (MeOH) ϫ 4) was chromatographed by similar conditions for fraction U7-B-1, except delivered by MeOH-0.1% FA aq 55:45, to yield M18 (0.3 mg, t R 29.8 min). Fraction U3-B [5.0 mg/50 l (MeOH-H 2 O 1:1) ϫ 11] was separated by similar conditions for fraction U7-B-1, except delivered by MeOH-0.1% FA aq 49:51, to give M9 (0.9 mg, t R 13.3-14.0 min), M14 (0.2 mg, t R 23.5-24.2 min), and a fraction (U3-B-2, 5.2 mg) containing other metabolites present in fraction U3-B.
13 C NMR spectra were acquired for these isolated metabolites, with the exception of M18; NOEDS spectra were acquired for M2 and M3; and HSQC and HMBC spectra were acquired for M9 and M14. HPLC-SPE-TT-NMR (600 MHz). For fraction U3-B-2, the HPLC conditions were as follows: an analytical column, the same as above; delivery system, MeOH-0.1% FA aq 42:58 to 44:56 in 40 min, to 74:26 in 30 min, to 90:10 in 0.1 min, all using linear gradient, and 90:10 for 10 min; amount injected: 705 g/15 l (MeOH) ϫ 3, flow rate: 0.6 ml/min, monitored at 260 nm. For fraction U8-2 [0.4 mg/10 l (MeOH) ϫ 3], the HPLC conditions were the same as those for fraction U3-B-2 except being delivered by an isocratic system, MeOH-0.1% FA aq 48:52. A makeup flow of pure water with a flow rate of 1.2 ml/min was added to the postcolumn eluent, and the mixed sample volume of each peak was passed through HySphere-Resin GP cartridges (10 ϫ 2 mm, 10 -12 m) in Prospekt 2 automated solid-phase extraction unit (Spark Holland, Emmen, the Netherlands). The metabolites with similar UV absorption to 1 ( max 260 nm), identified by RP-HPLC-DAD analysis, were trapped, respectively, by resin GP cartridge. The compound-loaded cartridges then were flushed with dry nitrogen for 30 min, and the individual cartridge was eluted with deuterated methanol into a 2-mm NMR tube via Gilson Liquid Handler 215 (Gilson, Inc., Middleton, WI). The 1 H NMR spectrum of each trapped compound was measured using the reported procedure .
HRESIMS and MS/MS Analyses. The time-of-flight mass spectrometry was used for measurements of accurate molecular weight of each metabolite. Both HPLC and direct-infusion HRESIMS were recorded under the following conditions: drying gas flow rate, 4.0 l/min; drying gas temperature, 180°C; nebulizer, 0.4 bar; capillary voltage, 3.9 and 4.1 kV for the positive and negative electrospray ionization modes, respectively; and mass range, 50 to 1000 Da. Esquire 2000 ion trap mass spectrometer was used for MS/MS measurement of M9, which was recorded under the following conditions: drying gas flow rate, 5.0 liter/min; drying gas temperature, 250°C; nebulizer, 5.0 psi; capillary voltage, 4.0 kV; fragmentation cutoff, 115 m/z; fragmentation amplification, 0.14 V; and mass range, 100 to 1000 Da.
Quantitative Analysis of Metabolites in Treated Urine. For quantitative analysis of 1 and metabolites in the urine residue of the treated group, the HPLC conditions were optimized further as follows: the same analytical RP-HPLC column as above; delivery system, MeOH-0.1% FA aq 35:65 for 5 min, to 70:30 in 50 min, both using linear gradient, and 70:30 for 5 min; sample amount injected: 10, 50, 100, 500, and 1000 ng/10 l (MeOH) for 1 in triplicate to obtain the calibration curve and 150 g/10 l (MeOH) in duplicate for the treated and control urine residues, whose preparation was the same as that described above. The metabolites were quantified according to the calibration curve of 1 (Supplemental Fig. S26 ).
Results
Metabolites Profiling in Rat Urine by HPLC Analysis. The initial RP-HPLC analysis of the urine residue of the treated group obtained from Wistar rats after intragastrical oral administration of (2S)-pterosin A (1), using the delivery system MeOH-0.1% FA aq as indicated under Materials and Methods, led to the detection of three major metabolites (M9, M14, and M19) and the parent compound (1) (Fig. 1) . Seven metabolite-containing fractions (U3-B, U3-B-2, U5, U7, U8, U8-2, and U10) were obtained by further fractionation of the urine residue of the treated group and its subfractions. Of these, fraction U3-B being a metabolite focusing subfraction was used for metabolites profiling study because the HPLC profile of fraction U3 showed very weak metabolite peaks. RP-HPLC and HPLC-MS analyses of these fractions led to the detection of M9 and M14 from fraction U3-B (Fig. 2a) ; M18 and M19 from fraction U5 (Fig. 2b) ; M1-3 from fraction U7 (Fig. 2c) ; M1, -2, and -10, and 1 from fraction U8 (Fig. 2d) ; M19 from fraction U10 (Fig. 2e) ; M4, -5, -7, -9, -11, -12, -14 -17, and -19 from fraction U3-B-2 (Fig. 3a) ; and M3, -6, -8, -10, and -13, and 1 from fraction U8-2 (Fig. 3b) .
Metabolites Profiling in Rat Feces by HPLC Analysis. RP-HPLC analysis of the MeOH extract of the feces of the treated group indicated the presence of only three additional compounds (M14, M19, and 1) compared with that of the control group (Fig. 1, c and d) .
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Further analyses of four metabolite-containing subfractions from the treated feces led to the detection of M14 from fractions F2 and F3; 1, M14, and M19 from fraction F4; and M19 from fraction F5 (Supplemental Fig. S2 ).
Structure Elucidation of the Phase I Metabolites (M1-4, -6 -8, -10, -11, -13, -14, and -16 -19). The structures of the phase I metabolites, with the exception of M1, M2, and M18, were characterized by HPLC-SPE-TT-NMR (Supplemental Figs. S3 and S4) from the contents in fractions U3-B-2 and U8-2. For further structure confirmation, seven metabolites, including M1, M2, and M18, were isolated by semi-preparative RP-HPLC from fractions U3-B (M9 and M14), U5-C (M18), U7-B (M1-3), and U10-B (M19). Of these, only M9 is a phase II metabolite.
Known Phase I Metabolites (M1, -3, -6, -8, -10, -18, and -19). Seven phase I metabolites are known and were identified as (2R,3S)-pterosin L (M1) Kuroyanagi et al., 1979a) (Fukuoka et al., 1972 (Fukuoka et al., , 1983 Kuroyanagi et al., 1979a) , (2R,3 S)-pterosin C (M6), (2S,3S)-pterosin C (M8) , (Ϯ)-pterosin P (M10) (Kuroyanagi et al., 1979b; Ouyang et al., 2010) , (Ϯ)-pterosin E (M18) (Yoshihira et al., 1971) , and (Ϯ)-pterosin B (M19) (Yoshihira et al., 1971; Sengupta et al., 1976) , respectively, by comparison of their spectroscopic data (MS, 1 H, 13 C NMR, NOEDS, and CD) ( Table 1; Supplemental Tables S1  and S2 ) with those reported in the literatures. Of these, M10, M18, and M19 were obtained as racemic form deduced from the transparent CD spectra.
C-14-Oxidized Metabolites (M4, -7, -14, and -16). M14 had a molecular formula of C 15 H 18 O 4 as deduced from HRESIMS (Table 1 ; Supplemental Fig. S5 ), having one oxygen more but 2H less than (2S)-pterosin A (1) and one equivalent of unsaturation more than 1. The 1 H NMR spectrum of M14 was very similar to that of 1 (Supplemental Figs. S3 and S4) by showing four singlets (H-4, Me-11, Me-12, and Me-15) and two AX systems (H 2 -3 and H 2 -10), with the exception of the replacement of an A 2 X 2 system for H 2 -13 and H 2 -14 in 1 by a two-proton singlet at ␦3.72 (Tables 2 and 3 ; Supplemental Figs. S3 and S4). These data indicated M14 to be the oxidation product of 1 at the C-14 position. In support of this suggestion the 13 C NMR spectrum of M14 showed an additional signal for a carboxylic group (␦175.5, C-14) and the absence of a methylene carbon signal (Table 3 ; Supplemental Fig. S6 ) in comparison with that of 1 (Supplemental Table S2 ). Therefore, the structure of M14 was established as (2S)-2-hydroxymethylpterosin E, which was confirmed by an (Table 1 ; Supplemental Fig. S8 ), having a CH 2 unit more than M14. The 1 H NMR spectrum of M16 was almost identical to that of M14, with the exception of the presence of an ester methyl signal at ␦3.67 (Table 2 ; Supplemental Fig. S4 ). Hence, M16 was simply the methyl ester of M14 and had a structure as shown. M7 had a molecular formula of C 15 H 18 O 5 as deduced from HRESIMS (Table 1; Supplemental Fig.  S9 ), having one oxygen atom more than M14. The 1 H NMR spectrum of M7 was similar to that of M14, with the exception the replacement of the AX system for H 2 -3 by a one-proton singlet, which was buried by ␦ HOD (Table 2; Supplemental Fig. S4 ). These data coupling with the CD curve (Supplemental Fig. S9 ) that showed a positive Cotton effect at 328 nm, similar to that of (2R,3R)-pterosin L (M3) (Kuroyanagi et al., 1979a) established M7 as the 3␣-hydroxylated M14, i.e., (2R,3R)-3-hydroxy-2-hydroxymethylpterosin E. M4 had the molecular formula of C 15 H 16 O 4 as deduced from HRESIMS (Table 1 ; Supplemental Fig. S8 ), having 2H less than M14. The 1 H NMR spectrum of M4 was similar to that of M14, with the exception that the Me-12 singlet in M14 was replaced by a two-proton singlet (␦5.39) (Table 2; Supplemental Fig. S4 ). On the basis of these data, M4 was elucidated as (S)-12-hydroxy-2-hydroxymethylpterosin E 14,12-lactone.
Other Phase I Metabolites (M2, -11, -13, and -17). M2 had the molecular formula of C 15 H 20 O 4 , as deduced from HRESIMS (Table  1 ; Supplemental Fig. S10) , showing one more oxygen atom than 1 while possessing the same equivalent of unsaturation as 1. The 1 H NMR spectra of M2 and 1 were similar, with the exception of the replacement of the Me-12 singlet (␦2.43) in 1 by a two-proton singlet at ␦4.75 (Table 3 ; Supplemental Fig. S10 ). The MS and 1 H NMR data, when combined, established M2 as (2S)-12-hydroxypterosin A, which was also supported by the enhancement of the H-4 singlet (␦7.43) upon irradiation at the frequency of this two-proton singlet (Supplemental Fig. S10 ). M13 and M17 had the same molecular formula of C 14 H 18 O 3 as deduced from HRESIMS (Table 1 ; Supplemental Figs. S8 and S11), having a CH 2 unit less than 1 and one oxygen atom more than M19 (Table 1 ; Supplemental Fig. S12 ). However, they had the same equivalent of unsaturation as 1. Compared with that of 1, the 1 H NMR spectrum of M17 (CD 3 OD) showed two additional singlets for methyl group and a carbonyl proton but lacked the A 2 X 2 system for H 2 -13 and H 2 -14 and the AX system for H 2 -3 (Table 2; Supplemental Fig. S4 ), suggesting a methyl group at C-6 and a hydroxyl group at C-3. These data when combined with the CD curve (Supplemental Fig. S11) , showing a positive Cotton effect at 327 nm similar to that of (2R,3R)-pterosin L (M3) (Kuroyanagi et al., 1979a) , established M17 as (2R,3R)-3-hydroxy-2-hydroxymethyl-2,5,6,7-tetramethyl-1-indanone or (2R,3R)-13-dehydroxymethylpterosin L. The 1 H NMR spectrum of M13 was also similar to that of (Ϯ)-pterosin B (M19) (Supplemental Table S1 ; Fig. S12 ), with the exception of the replacement of the A 2 X 2 system for H 2 -13 and H 2 -14 by an AMX system (␦5.29, 3.91, and 3.62, each dd) (Table 2; Supplemental Fig. S3 ). Accordingly, M13 was a C-13-hydroxylated derivative of M19. These data and the transparent CD curve thus established M13 as (Ϯ)-6-(1,2-dihydroxyethyl)-2,5,7-trimethyl-1-indanone or (Ϯ)-13-hydroxypterosin B. M11 had the molecular formula, C 15 H 16 O 4 , as deduced from 
HRESIMS data and quantitative analysis of each metabolite in urine
Calibration curve and regression equation of 1: y ϭ (5.89969 Ϯ 0.21303)x Ϫ (65.20 Ϯ 2.67), where y is peak area detected at 260 nm, x is the amount (10 -1000 ng, n ϭ 3) of 1. a Having the same retention time to the endogenous compound, and its amount being estimated from fraction U8-2 (Fig. 3b ) (see Results). b Three metabolites having the same retention time, and their amounts being estimated from the urine residue of the treated group (Fig. 4) , U3-B-2, and U8-2 (Fig. 3 ) (see Results). c Metabolites not detected in the urine residue of the treated group, and the amount estimated from fractions U3-B-2 and U8-2 (Fig. 3 ) (see Results). d Calculated by the amount of each metabolite/the amount of 1 (intragastrically administered) ϫ 100%.
( Table 1 ; Supplemental Figs. S14 and S15), reflecting a C 6 H 8 O 6 unit more than 1, equivalent to a glucuronyl (GlcUA) moiety. The major fragment ion at m/z 249 ([M-C 6 H 9 O 6 ϩ2H] ϩ ), observed in the electrospray ionization-MS/MS (Supplemental Fig. S14 ) of M9, also supported the presence of a GlcUA group. The 1 H NMR spectra of M9 and M12 showed the GlcUA H-1 at ␦4.32 and 4.24, respectively (Tables 3 and 2 ; Supplemental Figs. S14 and S4). Because the A 2 X 2 system for H 2 -13 and H 2 -14 in 1 was replaced by an A 2 MX system in M9, in which one of H 2 -14 signals was apparently downfield shifted (␦3.96 vs. 3.60), M9 thus was elucidated as (2S)-14-O-glucuronylpterosin A. In contrast, one of the H 2 -10 signals in M12 was downfield shifted significantly relative to that in 1 (␦4.07 vs. 3.70) ( Table 2) , establishing M12 as (2S)-10-O-glucuronylpterosin A. The HMBC spectrum of M9 showed the pair of correlations, H 2 -14/C-6 and C-1Ј (GlcUA C-1), and H-1Ј/C-14 (Table 3 ; Supplemental Fig.  S16 ), confirming M9 to be the 14-O-glucuronide of 1. By analysis of HMBC and HSQC spectra (Supplemental Fig. S17) , the complete 1 H and 13 C NMR assignments for M9 were made, and the data are provided in Table 3 . M5 had a molecular formula C 21 H 26 O 10 as deduced from HRESIMS (Table 1; Supplemental Fig. S15 ), containing one GlcUA residue (C 6 H 8 O 6 ) more than M14. A comparison of the respective 1 H NMR spectra also indicated their structural similarity, with the exception of the presence of additional signals for a glucuronyl residue in M5 (Table 2 ; Supplemental Fig. S4 ). The H 2 -10 signals in M5 and M9 were almost identical. Nevertheless, the GlcUA H-1 signal in M5 was downfield shifted relative to the corresponding signal in M9 (␦5.52 vs. 4.32) (Table 3) , suggesting a C-14 ester-linked glucuronyl conjugate in M5 as shown in the figure. M15 had a molecular formula of C 20 H 26 O 8 as deduced from HRESIMS (Table 1 ; Supplemental Fig. S15 ), having a GlcUA residue (C 6 H 8 O 6 ) more than M19. The 1 H NMR spectrum of M15 was similar to that of M19 (Supplemental Table S1 ), with the exception of the presence of additional signals corresponding to one GlcUA residue and the downfield-shifted H 2 -14 (␦3.95 and 3.64 vs. 3.59) ( Table 2 ; Supplemental  Fig. S4 ). These data suggested M15 to be a 14-O-␤-glucuronide of M19, i.e., 14-O-␤-glucuronylpterosin B.
Quantitative Analysis of Metabolites in Rat Urine. Almost all of these metabolites possessed the same indan-1-one chromophore, although M11 contained one additional conjugated lactone group. Thus, the calibration curve and regression equation of 1 in the linear range of 10 to 1000 ng (Table 1; Supplemental Fig. S26 ) were used to quantify these metabolites. For quantitative analysis of the metabolites of 1 in rat urine, an optimized RP-HPLC condition was used, and the HPLC profile of the urine residues of the treated and control groups was shown in Fig. 4 . Given that M8 was overlapped with an endogenous compound in urine (Fig. 4, compare a with b) , the minor metabolites M13 and M17 were obscure, and the retention times of M9 -11 were the same (Fig. 4a) ; the amounts of M8, -10, -11, -13, and -17 were estimated from their respective peak area ratio to 1 in fraction U8-2 (Fig. 3) . The amount of M9 was estimated by subtraction of those of M10 and M11 from the total amount calculated from the mixed peak in Fig. 4a . The summation of these metabolites led to the conclusion that ϳ71% (2S)-pterosin A (1) via intragastrical oral administration was excreted as metabolites through the urine route in rat (Table 1) .
Discussion
Nineteen metabolites (M1-19) of (2S)-pterosin A (1), including 15 phase I metabolites and four phase II conjugate, were characterized from rat urine, collected 24 h after intragastrical oral administration (100 mg/kg), by combining interpretation of their MS, NMR, and CD data. The major metabolites are (2S)-14-O-glucuronylpterosin A (Fig. 5) . The first one is benzylic oxidation at the C-3 (M1, -3, -6-8, and -17), C-12 (M2, -4, -10, and -11), and C-13 (M13) positions. The second one is oxidation of the alcoholic OH at the C-10 and C-14 positions to form the carboxylic function (M7, -14, and -18). The 3-one-1-oic acid metabolites such as A, obtained from oxidation at the C-10 position, however, were labile and decarboxylated, presumably through a mechanism similar to the six-center transition state (House, 1972) (Fig. 6 ) to form 2␣-dehydroxymethyl products (M6, -8, -10, -13, -18, and -19) . Such nonenzymatic decarboxylation was also observed in the carboxyl metabolite of compound LC15-0133 while treated with rat liver microsomes (Yoo et al., 2008) . The third one is lactonization of the carboxylic acid and the alcoholic groups to form the 12,14-lactone (M11) from intermediate B and the 14,12-lactone (M4) from intermediate C (Fig. 6 ). The minor metabolite M17 is a decarboxylated M7 and could be obtained via a mechanism similar to the decarboxylation of a 3-ene-1-oic acid as depicted (Fig. 6 ). Because the elimination of a carboxylic acid function located at the ␤-carbon next to the aryl group is very unusual, M17 was considered initially as impurity of (2S)-pterosin A (1). After examination of the retention times of M17 and those impurities (ϳ0.3% in total) observed in the HPLC profile of 1 used for this study (Supplemental Fig. S1 ), this possibility was eliminated. The presence of M16 could be interpreted as an artifact formed via reaction of methanol with the acyl glucuronide M5 during separation (Fig. 5) . As for the phase II metabolites, only glucuronide conjugates of the parent compound and two phase I metabolites, M14 and M19, were found in rat urine (Fig. 5) . No sulfate conjugates were detected in this study. The metabolism of pterosin family in vivo had not been previously investigated although the studies on 1-indanone containing com- FIG. 4 . Reverse-phase HPLC chromatograms of the urine residues (a, treated; b, control), monitored at UV 260 nm, under optimized conditions for quantitative analysis. Intens., intensity. pounds did show hydroxylation on 1-indanone substructure in rats microsomes (Coombs et al., 1985; Boyd et al., 1993) and in human (Brunel et al., 1995) . Our study reveals the amounts of 3␣-hydroxylated metabolites to be much more than those of 3␤-hydroxylated ones, similar to what was observed in dicentrine metabolites (Lai et al., 2010) and implying the regioselectivity of hydroxylation at C-3. The regioselectivity of benzylic hydroxylation also occurred in semagacestat metabolites, which were primarily formed by CYP3A4 and CYP3A5 (Yi et al., 2010) . The metabolites may be responsible for in vivo toxicological and pharmacological effects. (Ϯ)-Pterosin E (M18) and (Ϯ)-pterosin B (M19) have been shown to be cytotoxic against HeLa cells and HL-60 cells with the IC 50 values of 30 g/ml and 8.7 g/ml (Chen et al., 2008) , respectively. However, M3, M8, and M10 
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at ASPET Journals on August 14, 2017 dmd.aspetjournals.org Downloaded from possessed much weaker cytotoxicity Ouyang et al., 2010) . Nevertheless, M8 could enhance glucose consumption and the expression of glucose transporter 4 (Hsu et al., 2010) and thus could be considered as an active metabolite. The hypoglycemic effects of the other metabolites, especially three major ones (M9, M14, and M19), require further investigation.
